NCT04445519View on ClinicalTrials.gov

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

691

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

September 16, 2022

Study Completion Date

September 16, 2022

Conditions
Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

NCX 470 0.065% (initial phase of trial)

NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)

DRUG

Latanoprost 0.005% (initial phase of trial)

Latanoprost Ophthalmic Solution, 0.005%

DRUG

NCX 470 0.1% (initial phase of trial)

NCX 470 Ophthalmic Solution, 0.1%

DRUG

NCX 470 0.1% (remainder of trial)

NCX 470 Ophthalmic Solution, 0.1%

DRUG

Latanoprost 0.005% (remainder of trial)

Latanoprost Ophthalmic Solution, 0.005%

Trial Locations (1)

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors
lead

Nicox Ophthalmics, Inc.

INDUSTRY

NCT04445519 - Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter